Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer

Current Topics in Medicinal Chemistry

Volumn 5, Issue 5, 2005, Pages 493-503

  Benamouzig, Robert ^a   Uzzan, Bernard ^a   Little, Julian ^b   Chaussade, Stanislas ^c  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Hôpital Cochin ^*  (France)

Author keywords

Aspirin; Chemoprevention; Colorectal carcinoma; COX 2

Indexed keywords

ACETYLSALICYLIC ACID; BALSALAZIDE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; LYSINE ACETYLSALICYLATE; MESALAZINE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OLSALAZINE; PARACETAMOL; PIROXICAM; PLACEBO; ROFECOXIB; SALICYLATE SODIUM; SULINDAC; SULINDAC SULFONE;

CANCER INCIDENCE; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; COLON RESECTION; COLORECTAL ADENOMA; COLORECTAL CANCER; DIARRHEA; DRUG METABOLISM; ENZYME INHIBITION; FAMILIAL COLON POLYPOSIS; GASTROINTESTINAL TOXICITY; HUMAN; IN VIVO STUDY; LOW DRUG DOSE; NEUTROPENIA; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT;

ADENOMA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; HUMANS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS;

EID: 22144441710     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026054201631     Document Type: Review

References (216)

1. Janne, P.A., Mayer, R.J. Chemoprevention of colorectal cancer. N. Engl. J. Med. 2000, 342, 1960-8.
2. Kelloff, G.J., Johnson, J.R., Crowell, J.A., et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol. Biomarkers Prev. 1995, 4, 1-10.
3. Hawk, E., Lubet. R., Limburg, P., Chemoprevention in hereditary colorectal cancer syndromes. Cancer 1999, 86, 2551-63.
4. IARC Working Group on the Evaluation of Cancer Preventive Agents. Non-Steroidal Anti-Inflammatory Drugs. Lyon, International Agency for Research on Cancer. World Health Organization, 1997. IARC Handbooks of Cancer Prevention; vol 1.
5. Reddy, B.S., Murujama, H., Kelloff, G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a non steroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res. 1987, 47, 5340-6.
6. Reddy, B.S., Nayini, J., Tokumo, K., Rigotty, J., Zang, E., Kelloff, G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L, α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res. 1990, 50, 2562-8.
7. Rao, C.V., Tokumo, K., Rigotty, J.E., Zang Keloff. G., Reddy, B. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, a-difluoromethylornithine, 16-a-fluoro-5-androsten-17-one and ellegic acid individually and in combination. Cancer Res. 1991, 51, 4528-34.
8. Craven, P.A., DeRubertis, F.R. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. Carcinogeneis 1992, 13, 541-6.
9. Reddy, B.S., Tokumo, K., Kulkarni, N., Aligia, C., Kelloff, G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992, 13, 1019-23.
10. Reddy, BS., Rao, CV., Rivenson, A., Keloff, G., Inhibitory effect of aspirin on azoxymethane induced colon carcinogenesis in F344 rats. Carcinogenesis 1993, 14, 1493-7.
11. Davis, A.E., Patterson, F. Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model. Australian New Zealan J. Med. 1994, 24, 301-3.
12. Rao, C.V., Rivenson, A., Simi, B., et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 1995, 55, 1464-72.
13. Piazza, G.A., Alberts, D.S., Hixson, L.J., et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997, 57, 2909-15.
14. Fukutake, M., Nakatsugi, S., Isoi, T., et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 1998, 19, 1939-42.
15. Reddy, B.S., Kawamori, T., Lubet, R.A., Steele, V.E., Kelloff, G.J., Rao, C.V. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res. 1999, 59, 3387-91.
16. Li, H., Schut, H.A., Conran, P., et al. Prevention by aspirin and its combinationwith alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 1999, 20, 425-30.
17. Li, H., Kramer, P.M., Lubet, R.A., Steele, V.E., Kelloff, G.J., Pereira, M.A. Termination of piroxicam treatment and the occurrence of azoxymethane-induced colon cancer in rats. Cancer Lett. 1999, 147, 187-93.
18. Tao, L., Kramer, P.M., Wang, W., et al. Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents. Carcinogenesis 2002, 23, 1447-54.
19. Zhang, Z., Li, J., Lantry, L.E., et al. p53 transgenic mice are highly susceptible to 1, 2-dimethylhydrazine-induced uterine sarcomas. Cancer Res. 2002, 62, 3024-9.
20. Falkowski, M., Skogstad, S., Shahzidi, S., Smedsrod, B., Sveinbjornsson, B. The effect of cyclooxygenase inhibitor diclofenac on experimental murine colon carcinoma. Anticancer Res. 2003, 23, 2303-8.
21. Oshima, M., Dinchuk, J.E., Kargman, S.L., et al. Suppression of intestinal polyposis in Ape delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87, 803-9.
22. Boolbol, S.K., Dannenberg, A.J., Chadburn, A., et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996, 56, 2556-60.
23. Chiu, C.H., McEntee, M.F., Whelan, J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res. 1997, 57, 4267-73.
24. Barnes, C.J., Lee, M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 1998, 114, 873-7.
25. Ritland, S.R., Leighton, J.A., Hirsch, R.E., Morrow, J.D., Weaver, A.L., Gendler, S.J. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention, lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse. Clin. Cancer Res. 1999, 5, 855-63.
26. Jacoby, R.F., Cole, C.E., Tutsch, K., et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 2000, 60, 1864-70.
27. Wechter, W.J., Murray, E.D. Jr., Kantoci, D., et al. Treatment and survival study in the C57BL/6J-APC(Min)/+(Min) mouse with R-flurbiprofen. Life Sci. 2000, 66, 745-53.
28. Torrance, C.J., Jackson, P.E., Montgomery, E., et al. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 2000, 6, 1024-8.
29. Sansom, O.J., Stark, L.A., Dunlop, M.G., Clarke, A.R. Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice. Cancer Res. 2001, 61, 7060-4.
30. Lal, G., Ash, C., Hay, K., et al. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res. 2001, 61, 6131-6.
31. Suganuma, M., Ohkura, Y., Okabe, S., Fujiki, H. Combination cancer chemoprevention with green tea extract and sulindac shown in intestinal tumor formation in Min mice. J. Cancer Res. Clin. Oncol. 2001, 127, 69-72.
32. Reuter, B.K., Zhang, X.J., Miller, M.J. Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis. BMC Cancer 2002, 2, 19.
33. Yang, K., Fan, K., Kurihara, N., et al. Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations. Carcinogenesis 2003, 24, 605-11.
34. Corpet, D.E., Pierre, F. Point, From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol. Biomarkers Prev. 2003, 12, 391-400.
35. Williams, J.L., Kashfi, K., Ouyang, N., del Soldato, P., Kopelovich, L., Rigas, B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem. Biophys. Res. Commun. 2004, 313, 784-788.
36. Qiu, Z.F., Maruyama, K., Sunayama, K., et al. Piroxicam-induced regression of intestinal adenomatous polyps in APC(delta474) mice. J. Invest. Surg. 2003, 16, 71-81.
37. Benamouzig, R. Do aspirin or nonsteroidal anti-inflammatory drugs decrease the risk of colorectal cancer?. Gastroenterol Clin. Biol. 1998, 22, S22-7.
38. Mereto, E., Frencia, L., Ghia, M. Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine. Cancer Letters 1994, 76, 5-9.
39. Pereira, M.A., Barnes, L.H., Rassman, V.L., Kelloff, G.V., Steele, V.E. Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 1994, 15, 1049-54.
40. Wargovich, M.J., Chen, C.D., Harris, C., Yang, E., Velasco, M. Inhibition of aberrant crypt growth by non-steroidal antiinflammatory agents and differentiation agents in the rat colon. Int. J. Cancer 1995, 60, 515-9.
41. Wargovich, M.J., Chen, C.D., Jimenez, A., et al. Aberrant crypts as a biomarker for colon cancer, evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol. Biomarkers Prev. 1996, 5, 355-60.
42. Barnes, C.J., Hardman, W.E., Cameron, I.L., Lee, M. Aspirin, but not sodium salicylate, indomethacin, or nabumetone, reversibly suppresses 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats. Dig. Dis. Sci. 1997, 42, 920-6.
43. Morishita, Y., Yoshimi, N., Kawabata, K., et al. Regressive effects of various chemopreventive agents on azoxymethane-induced aberrant crypt foci in the rat colon. Jpn J. Cancer Res. 1997, 88, 815-20.
44. Pereira, M.A. Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDs. Adv. Exp. Med. Biol. 1999, 470, 55-63.
45. Wargovich, M.J., Jimenez, A., McKee, K., et al. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 2000, 21, 1149-55.
46. Waddell, W.R., Loughry, R.W. Sulindac for polyposis of the colon. J. Surg. Oncol. 1983, 24, 83-7.
47. Gonzaga, R.A.F., Lima, F.R., Carneiro, S., Maciel, J., Junior, M.A. Sulindac treatment for familial polyposis coli. Lancet 1985, 1, 751.
48. Waddell, W.R., Ganser, G.F., Cerise, E.J., Loughry, R.W. Sulindac for polyposis of the colon. Am. J. Surg. 1989, 157, 175-9.
49. Charneau, J.D., D'Aubigny, N., Burtin, P., Person, B., Boyer, J. Micropolypes rectaux après colectomie totale pour polypose familiale. Efficacité du sulindac. Gastroenterol Clin. Biol. 1990, 14, 153-7.
50. Friend, W.G. Sulindac suppression of colorectal polyps in Gardner's syndrome. Am. Fam. Physician 1990, 41, 891-4.
51. Rigau, J., Pique, J.M., Rubio, E., Planas, R., Tarrech, J.M., Bordas, J.M. Effects of long term sulindac therapy on colonic polyposis. Ann. Intern. Med. 1991, 115, 952-4.
52. Tonelli, F., Valanzano, R. Sulindac in familial adenomatous polyposis. Lancet 1993, 342, 1120.
53. Makela, J.T., Laitinen, S. Sulindac therapy for familial adenomatous polyposis after colectomy and ileorectal anastomosis. Ann. Chir. Gynaecol 1994, 83, 265-7.
54. Spagnesi, M.T., Tonelli, F., Dolara, P., et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994, 106, 362-6.
55. Muller, A., Hurlimann, R., Meyenberger, C., Staub, P., Kobler, E., Ammann, R. [Sulindac in familial adenomatous polyposis coli-preliminary findings of a prospective study]. Schweiz Med Wochenschr 1994, 124, 651-4.
56. Debinski, H.S., Trojan, J., Nugent, K.P., Spigelman, A.D., Phillips, R.K. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 1995, 345, 855-6.
57. Cerdan, F.J., Torres-Melero, J., Martinez, S., Gutierrez del Olmo, A., Balibrea, J.L. Treatment with sulindac of adenomatous polyps in familial polyposis. Rev. Esp. Enferm. Dig. 1995, 87, 574-6.
58. Kadmon, M., Moslein, G., Buhr, HJ., Herfarth, C., Desmoid tumors in patients with familial adenomatous polyposis (FAP). Clinical and therapeutic observations from the Heidelberg polyposis register. Chirurg 1995, 66, 997-1005.
59. Seow-Choen, F., Vijayan, V., Keng, V. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis. Br. J. Surg. 1996, 83, 1763-6.
60. Okai, T., Yamaguchi, Y., Sakai, J., Ohtsubo, K., Mouri, H., Sawabu, N. Complete regression of colonic adenomas after treatment with sulindac in Gardner's syndrome, a 4-year follow-up. J. Gastroenterol. 2001, 36, 778-82.
61. Esaki, M., Matsumoto, T., Mizuno, M., et al. Effect of sulindac treatment for attenuated familial adenomatous polyposis with a new germline APC mutation at codon 161, report of a case. Dis. Colon. Rectum. 2002, 45, 1397-402.
62. Winde, G., Schmid, K.W., Brandt, B., Muller, O., Osswald, H. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis. Colon. Rectum. 1997, 40, 1156-68.
63. Guldenschuh, I., Hurlimann, R., Muller, A., et al. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis. Dis. Colon. Rectum. 2001, 44, 1090-7.
64. Giardiello, F.M., Offerhaus, J.A., Tersmette, A.C., et al. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis, evaluation of predictive factors. Gut. 1996, 38, 578-81.
65. Labayle, D., Fischer, D., Vielh, P., et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991, 101, 635-9.
66. Nugent K.P., Farmer, K.C.R., Spigelman, A.D., Williams C.B., Phillips R.K.S. Randomised controlled trial of sulindac on intestinal polyposis in FAP. Gut 1992, 33, S33.
67. Giardiello, F.M., Hamilton, S.R., Krush, A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 1993, 328, 1313-6.
68. Giardiello, F.M., Yang, V.W., Hylind, L.M., et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med. 2002, 346, 1054-9.
69. Cruz-Correa, M., Hylind, L.M., Romans, K.E., Booker, S.V., Giardiello, F.M. Long-term treatment with sulindac in familial adenomatous polyposis, a prospective cohort study. Gastroenterology 2002, 122, 641-5.
70. Tonelli, F., Valanzano, R., Messerini, L., Ficari, F. Long-term treatment with sulindac in familial adenomatous polyposis, is there an actual efficacy in prevention of rectal cancer? J. Surg. Oncol. 2000, 74, 15-20.
71. Keller, J.J., Offerhaus, G.J., Drillenburg, P., et al. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clin. Cancer Res. 2001, 7, 4000-7.
72. Niv, Y., Fraser, G.M. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 1994, 107, 854-7.
73. Thorson, A.G., Lynch, H.T., Smyrk, T.C. Rectal cancer in FAP patient after sulindac. Lancet 1994, 343, 180.
74. Lynch, H.T., Thorson, A.G., Smyrk, T. Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer 1995, 75, 936-8.
75. Utech, M., Bruwer, M., Buerger, H., Tubergen, D., Senninger, N. Rectal carcinoma in a patient with familial adenomatous polyposis coli after colectomy with ileorectal anastomosis and consecutive chemoprevention with sulindac suppositories. Chirurg 2002, 73, 855-8.
76. Ladenheim, J., Garcia, G., Titzer, D., et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995, 108, 1083-7.
77. Matsuhashi, N., Nakajima, A., Fukushima, Y., Yazaki, Y., Oka, T. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut. 1997, 40, 344-9.
78. Ishikawa, H., Akedo, I., Suzuki, T., Narahara, H., Otani, T. Adverse effects of sulindac used for prevention of colorectal cancer. J. Natl. Cancer Inst. 1997, 89, 1381.
79. Stoner, G.D., Budd, G.T., Ganapathi, R., et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv. Exp. Med. Biol. 1999, 470, 45-53.
80. van Stolk, R., Stoner, G., Hayton, W.L., et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin. Cancer Res. 2000, 6, 78-89.
81. Burke, C.A., Bauer, W.M., Lashner, B. Chemoprevention of colorectal cancer, slow, steady progress. Cleve. Clin. J. Med. 2003, 70, 346-50.
82. Isomaki, H.A., Hakulinen, T., Joutsenlahti, U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J. Chronic Dis. 1978, 31, 691-6.
83. Laakso, M., Mutru, O., Isomaki, H., Koota, K. Cancer mortality in patients with rheumatoid arthritis. J. Rheumatol. 1986, 13, 522-6.
84. Gridley, G., McLaughlin, J.K., Ekbom, A., et al. Incidence of cancer among patients with rheumatoid arthritis. J. Natl. Cancer Instit. 1993, 85, 307-10.
85. Kauppi, M., Pukkala, E., Isomaki, H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 1996, 14, 551-3.
86. Suh, O., Mettlin, C., Petrelli N.J. Aspirin use, cancer and polyps of the large bowel. Cancer 1993, 72, 1171-7.
87. Logan, R.F.A., Little, J., Hawtin, P.G., Harcastle, J.D. Effect of aspirin and non-steroidal drugs on colorectal adenomas, case-control study of subjects participating in the Nottingham faecal occult screening programme. Br. Med. J. 1993, 307, 285-9.
88. Wishingrad, M., Titzer, D., Triadafopoulos, G., Omary, B. Chronic aspirin and NSAID use may protect against colorectal adenomas. Gastroenterology 1994, 112, A452.
89. Johanson, J.F., Salisbury, D. Effectiveness of aspirin in preventing colorectal adenomas, does dose matter? Gastroenterology 1995, 114, A606.
90. Greenberg, E.R., Baron, J.A., Freeman D.J, Mandel J.S, Haile R. Reduced risk of large-bowel adenomas among aspirin users. J. Natl. Cancer Instit. 1993, 85, 912-6.
91. Tosteson, T., Greenberg, E., Baron, J. Aspirin use and reduced occurence of large bowel adenomas. Gastroenterology 1995, 108, A39.
92. Macrae, F.A., Russell, A., MacLennan, R. Aspirin effects on large adenomas. Gastroenterology 1994, 112, A413.
93. Martinez, M.E., McPherson, R.S., Levin, B., Annegers, J.F. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol. Biomarkers Prev. 1995, 4, 703-7.
94. Martinez, M.E., McPherson, R.S., Levin, B., Glober, G.A. A case-control study of dietary intake and other lifestyle risk factors for hyperplastic polyps. Gastroenterology 1997, 113, 423-9.
95. Sandler, R.S., Galanko, J.C., Murray, S.C., Helm, J.F., Woosley, J.T. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998, 114, 441-7.
96. Kahn, H.S., Tatham, L.M., Thun, M.J, Heath C.W. Jr. Risk factors for self-reported colon polyps. J. Gen. Intern. Med. 1998, 13, 303-10.
97. Breuer-Katschinski, B., Nemes, K., Rump, B., et al. Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group Digestion 2000, 61, 129-34.
98. Garcia Rodriguez, L.A., Huerta-Alvarez, C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs, a pooled analysis of published studies and a new population-based study. Epidemiology 2000, 11, 376-81.
99. Kune, G.A., Kune, S., Watson, L.F. Colorectal cancer risk, chronic illness, operations and medications, case-control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988, 48, 4399-4404.
100. Rosenberg, L., Palmer, J.R., Zauber, A.G., Warshauer, M.E., Stolley, P.D., Schapiro, S. A hypothesis, non-steroidal antiinflammatory drugs reduce the incidence of large bowel cancer. J. Natl. Cancer Instit. 1991, 83, 355-8.
101. Muscat, J.E., Stellman, S.D., Wynder, E.L. Nonsteroidal antiinflammatory drus and colorectal cancer. Cancer 1994, 74, 1847-54.
102. Muller, A.D., Sonnenberg, A., Wasseman, I.H. Diseases preceding colon cancer. A case control study among veterans. Dig. Dis. Sci. 1994, 39, 2480-4.
103. Peleg, I.I., Maibach, H.T., Brown, S.H., Wilcox, C.M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch. Intern. Med. 1994, 154, 394-9.
104. Evans, JMM., McMahon, AD., McGilchrist, MM., et al. Non-steroidal anti-inflammatory drugs, aspirin and colorectal cancer, a record linkage case control study in Tayside, Scotland. Gastroenterology 1995, 114, A608.
105. Reeves, M.J., Newcomb, P.A., Trentham-Dietz, A., Storer, B.E., Remington, P.L. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol. Biomarkers Prev. 1996, 5, 955-60.
106. La Vecchia, C., Negri, E., Franceschi, S., et al. Aspirin and colorectal cancer. Br. J. Cancer 1997, 76, 675-7.
107. Rosenberg, L., Louik, C., Shapiro, S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998, 82, 2326-33.
108. Neugut, A.I., Rosenberg, D.J., Ahsan, H., et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol. Biomarkers Prev. 1998, 7, 869-73.
109. Bucher, C., Jordan, P., Nickeleit, V., Torhorst, J., Mihatsch, M.J. Relative risk of malignant tumors in analgesic abusers. Effects of long-term intake of aspirin. Clin. Nephrol. 1999, 51, 67-72.
110. Smalley, W., Ray, W.A., Daugherty, J., Griffin, M.R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer, a population-based study. Arch. Intern. Med. 1999, 159, 161-6.
111. Collet, J.P., Sharpe, C., Belzile, E., Boivin, J.F., Hanley, J., Abenhaim, L. Colorectal cancer prevention by non-steroidal antiinflammatory drugs, effects of dosage and timing. Br. J. Cancer 1999, 81, 62-8.
112. Coogan, P.F., Rosenberg, L., Louik, C., et al. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control 2000, 11, 249-55.
113. Langman, M.J., Cheng, K.K., Gilman, E.A., Lancashire, R.J. Effect of anti-inflammatory drugs on overall risk of common cancer, case-control study in general practice research database. Br. Med. J. 2000, 320, 1642-6.
114. Garcia-Rodriguez, L.A., Huerta-Alvarez, C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 2001, 12, 88-93.
115. Juarranz, M., Calle-Puron, M.E., Gonzalez-Navarro, A., et al. Physical exercise, use of Plantago ovata and aspirin, and reduced risk of colon cancer. Eur. J. Cancer Prev. 2002, 11, 465-72.
116. Shpitz, B., Klein, E., Buklan, G., et al. Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut. 2003, 52, 1598-601.
117. Bigler, J., Whitton, J., Lampe, J.W., Fosdick, L., Bostick R.M., Potter, J.D. CYP2C9 and UGTIA6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 2001, 61, 3566-9.
118. Martinez, M.E., O'Brien, T.G., Fultz, K.E., et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc. Natl. Acad. Sci. USA 2003, 100, 7859-64.
119. Paganini-Hill, A., Chao, A., Ross, R.K., Henderson, B.E. Aspirin use and chronic diseases, a cohort study of the elderly. Br. Med. J. 1989, 299, 1247-50.
120. Paganini-Hill, A., Hou, G., Ross, R.K., Henderson, B.E. Aspirin use and incidence of large bowel cancer in a California retirement community. J. Natl. Cancer Instit. 1991, 83, 1182-3.
121. Paganini-Hill, A., Hsu, G., Ross, R.K., Henderson, B.E. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 1992, 326, 1290.
122. Stemmermann, G.N., Nomura, A.M.Y., Grove, J.S. Aspirin and colonic epithelium. Gastroenterology 1989, 96, 270-1.
123. Schreinemachers, D.M., Everson, R.B. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 1994, 5, 138-146.
124. Thun, M.J., Namboodiri, M.M., Heath, C.W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 1991, 325, 1593-96.
125. Thun, M.J., Namboodiri, M.M., Calle, E.E., Flanders, W.D., Heath, C.W. Aspirin use and risk of fatal cancer. Cancer Res. 1993, 53, 1322-27.
126. Giovanucci, E., Rimm, E.B., Stampfer, M.J., Colditz, G.A., Ascherio, A. Willett, WC., Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 1994, 121, 241-6.
127. Giovanucci, E., Egan, K.M., Hunter, D.J., et al. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 1995, 333, 609-14.
128. Friis, S., Sorensen, H.T., McLaughlin, J.K., Johnsen, S.P., Blot W.J., Olsen, J.H. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br. J. Cancer 2003, 88, 684-8.
129. Tangrea, J.A., Albert, P.S., Lanza, E., et al. Non-steroidal antiinflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control 2003, 14, 403-11.
130. Paganini-Hill, A. Aspirin and colorectal cancer, the Leisure World cohort revisited. Prev. Med. 1995, 24, 113-5.
131. Gann, P.H., Manson, J.E., Glynn, R.J., Buring, J.E., Hennekens, C.H. Low-dose aspirin use and incidence of colorectal tumors in a randomized trial. J. Natl. Cancer Instit. 1993, 85, 1120-24.
132. Sturmer, T., Glynn, R.J., Lee, I.M., Manson, J.E., Buring, J.E., Hennekens, C.H. Aspirin use and colorectal cancer, post-trial follow-up data from the Physicians' Health Study. Ann. Intern. Med. 1998, 128, 713-20.
133. Sandler, R.S., Halabi, S., Baron, J.A., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 2003, 348, 883-90.
134. Baron, J.A., Cole, B.F., Sandler, R.S., et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 2003, 348, 891-9.
135. Benamouzig, R., Yoon, H., Little, J., et al. APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence, design and baseline findings. Eur. J. Cancer Prev. 2001, 10, 327-35.
136. Benamouzig, R., Deyra, J., Martin, A., et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence, one-year results of the APACC trial. Gastroenterology 2003, 125, 328-36.
137. Mathers, J.C., Mickleburgh, I., Chapman, P.C., Bishop, D.T., Burn, J. Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study, Proc. Nutr. Soc. 2003, 62, 51-7.
138. Ladabaum, U., Chopra, C.L., Huang, G., Scheiman, J.M., Chernew, M.E., Fendrick, A.M. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann. Intern. Med. 2001, 135, 769-81.
139. Suleiman, S., Rex, D.K. Sonnenberg, A., Chemoprevention of colorectal cancer by aspirin, a cost-effectiveness analysis. Gastroenterology 2002, 122, 78-84.
140. Pinczowski, D., Ekbom, A., Baron, J., Yuen, J., Adami, H.O. Risk factors for colorectal cancer in patients with ulcerative colitis, a case-control study. Gastroenterology 1994, 107, 117-20.
141. Bansal, P., Sonnenberg, A., Risk factors of colorectal cancer in inflammatory bowel disease. Am. J. Gastroenterol. 1996, 91, 44-8.
142. Eaden, J., Abrams, K., Ekbom, A., Jackson, E., Mayberry, J. Colorectal cancer prevention in ulcerative colitis, a case-controt study. Aliment. Pharmacol. Ther. 2000, 14, 145-53.
143. Bus, P.J., Nagtegaal, I.D., Verspaget, H.W., et al. Mesalazine-induced apoptosis of colorectal cancer, on the verge of a new chemopreventive era? Aliment. Pharmacol. Ther. 1999, 13, 1397-402.
144. Brown, WA., Farmer, KC., Skinner, SA., Malcontenti-Wilson, C., Misajon, A., O'Brien PE. 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig. Dis. Sci. 2000, 45, 1578-84.
145. Narisawa, T., Fukaura, Y. Prevention by intrarectal 5-aminosalicylic acid of N-methylnitrosourea-induced colon cancer in F344 rats. Dis. Colon. Rectum. 2003, 46, 900-3.
146. MacGregor, D.J., Kim, Y.S., Sleisenger, M.H., Johnson, L.K. Chemoprevention of colon cancer carcinogenesis by balsalazide, inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+ mouse. Int. J. Oncol. 2000, 17, 173-9.
147. Paterson, J.R., Lawrence, J.R. Salicylic acid, a link between aspirin, diet and the prevention of colorectal cancer. Quartely J. Med. 2001, 94, 445-8.
148. Blacklock, C.J., Lawrence, J.R., Wiles, D., et al. Salicylic acid in the serum of subjects not taking aspirin. Comparison of salicylic acid concentrations in the serum of vegetarians, non-vegetarians, and patients taking low dose aspirin. J. Clin. Pathol. 2001, 54, 553-5.
149. Lawrence, J.R., Peter, R., Baxter, G.J., Robson, J., Graham, A.B., Paterson, J.R. Urinary excretion of salicyluric and salicylic acids by non-vegetarians, vegetarians, and patients taking low dose aspirin. J. Clin. Pathol. 2003, 56, 651-3.
150. Ruffin, M.T., Krishnan, K., Kraus, E. Aspirin as a chemopreventive agent for colorectal cancer, lowest dose of aspirin to suppress rectal mucosal prostaglandins. Proc. Am. Assoc. Cancer Res. 1995, 36, 600.
151. Ruffin, M.T.T., Krishnan, K., Rock, C.L., et al. Suppression of human colorectal mucosal prostaglandins, determining the lowest effective aspirin dose. J. Natl. Cancer Inst. 1997, 89, 1152-60.
152. Marnett, L.J., DuBois, R.N. COX-2, A Target for Colon Cancer Prevention. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 55-80.
153. Tsuji, S., Kawano, S., Sawaoka, H., et al. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot Essent Fatty Acids 1996, 55, 179-83.
154. Shao, J., Sheng, H., Inoue, H., Morrow, J.D., DuBois, R.N. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J. Biol. Chem. 2000, 275, 33951-6.
155. Chen, W.S., Wei, S.J., Liu, J.M., Hsiao, M., Kou-Lin, J., Yang, W.K. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int. J. Cancer 2001, 91, 894-9.
156. Tsujii, M., DuBois, R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83, 493-501.
157. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., DuBois, R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93, 705-16.
158. Sheng, H., Shao, J., Kirkland, S.C., et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 1997, 99, 2254-9.
159. Swamy, M.V., Herzog, C.R., Rao, C.V. Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res. 2003, 63, 5239-42.
160. Elder, D.J., Halton, D.E., Hague, A., Paraskeva, C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal antiinflammatory drug, independence from COX-2 protein expression. Clin. Cancer Res. 1997, 3, 1679-83.
161. Sheng, H., Shao, J., Morrow, J.D., Beauchamp, R.D., DuBois, R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998, 58, 362-6.
162. Li, M., Wu, X., Xu, XC., Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin. Cancer Res. 2001, 7, 1010-6.
163. Elder, D.J., Halton, D,E., Crew, T.E., Paraskeva, C. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int. J. Cancer 2000, 86, 553-60.
164. Chen, W.S., Liu, J.H., Wei, S.J., Liu, J.M., Hong, C.Y., Yang, W.K. Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor. Cancer Sci. 2003, 94, 253-8.
165. Elder, D.J., Halton, D.E., Playle, L.C., Paraskeva, C. The MEK/ERK pathway mediates COX-2-sclective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int. J. Cancer 2002, 99, 323-7.
166. Arico, S., Pattingre, S., Bauvy, C., et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem. 2002, 277, 27613-21.
167. Tang, X., Sun, Y.J., Half, E., Kuo, M.T., Sinicrope, F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 2002, 62, 4903-8.
168. He, Q., Luo, X., Huang, Y., Sheikh. M.S. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. Oncogene 2002, 21, 6032-40.
169. Smartt, H.J., Elder, D.J., Hicks, D.J., Williams, N.A., Paraskeva, C. Increased NF-kappaB DNA binding but not transcriptional activity during apoptosis induced by the COX-2-selective inhibitor NS-398 in colorectal carcinoma cells. Br. J. Cancer 2003, 89, 1358-65.
170. Kishimoto, Y., Morisawa, T., Hosoda, A., Shiota, G., Kawasaki, H., Hasegawa, J. Molecular changes in the early stage of colon carcinogenesis in rats treated with azoxymethane. J. Exp. Clin. Cancer Res. 2002, 21, 203-11.
171. DuBois, R.N., Radhika, A., Reddy, B.S., Entingh, A.J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996, 110, 1259-62.
172. Williams, C.S., Luongo, C., Radhika, A., et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996, 111, 1134-40.
173. Reddy, B.S., Rao, C.V., Seibert, K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 1996, 56, 4566-9.
174. Yoshimi, N., Kawabata, K., Hara, A., Matsunaga, K., Yamada, Y., Mori, H. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn. J. Cancer Res. 1997, 88, 1044-51.
175. Kawamori, T., Rao, C.V., Seibert, K., Reddy, B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998, 58, 409-12.
176. Wei, M., Morimura, K., Wanibuchi, H., et al. Chemopreventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on 1,2-dimethylhydrazine-induced rat colon carcinogcnesis. Cancer Lett. 2003, 202, 11-6.
177. Nakatsugi, S., Fukutake, M., Takahashi, M., et al. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn. J. Cancer Res. 1997, 88, 1117-20.
178. Sasai, H., Masaki, M., Wakitani, K. Suppression of polypogenesis in a new mouse strain with a truncated Apc(Delta474) by a novel COX-2 inhibitor, JTE-522. Carcinogenesis 2000, 21, 953-8.
179. Jacoby, R.F., Seibert, K., Cole, C.E., Kelloff, G., Lubet, R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 2000, 60, 5040-4.
180. Oshima, M., Murai, N., Kargman, S., et al. Chemoprevention of intestinal polyposis in the Apedelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 2001, 61, 1733-40.
181. Evans, J.F. Rofecoxib (vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer. Am. J. Clin. Oncol. 2003, 26, S62-5.
182. Williams, C.S., Sheng, H., Brockman, J.A., et al. A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia 2001, 3, 428-36.
183. Kishimoto, Y., Yashima, K., Morisawa, T., Shiota, G., Kawasaki, H., Hasegawa, J. Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane. J. Gastroenterol. 2002, 37, 186-93.
184. Kakiuchi, Y., Tsuji, S., Tsujii, M., et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res. 2002, 62, 1567-72.
185. Nagatsuka, I., Yamada, N., Shimizu, S., et al. Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer. Int. J. Cancer 2002, 100, 515-9.
186. Kargman, S., Charleson, S., Cartwright, M., et al. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996, 111, 445-54.
187. Kargman, S.L., O'Neill, G.P., Vickers, P.J., Evans, J.F., Mancini, J.A., Jothy, S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 1995, 55, 2556-9.
188. Eberhart, C.E., Coffey, R.J., Radhika, A., Giardiello, F.M., Ferrenbach, S., Dubois, R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107, 1183-8.
189. Maekawa, M., Sugano, K., Sano, H., et al. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn. J. Clin. Oncol. 1998, 28, 421-6.
190. Shattuck-Brandt, R.L., Lamps, L.W., Heppner, Goss, K.J., DuBois, R.N., Matrisian, L.M. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol. Carcinog 1999, 24, 177-87.
191. Hao, X., Bishop, A.E., Wallace, M., et al. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J. Pathol. 1999, 187, 295-301.
192. Sinicrope, F.A., Lemoine, M., Xi, L., et al. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 1999, 117, 350-8.
193. Bamba, H., Ota, S., Kato, A., Adachi, A., Itoyama, S., Matsuzaki, F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int. J. Cancer 1999, 83, 470-5.
194. Fujita, M., Fukui, H., Kusaka, T., Ueda, Y., Fujimori, T. Immunohistochemical expression of cyclooxygenasc (COX)-2 in colorectal adenomas. J. Gastroenterol. 2000, 35, 488-90.
195. Chapple, K.S., Cartwright, E.J., Hawcroft, G., et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am. J. Pathol. 2000, 156, 545-53.
196. Arao, J., Sano, Y., Fujii, T., et al. Cyclooxygenase-2 is overexpressed in serrated adenoma of the colorectum. Dis. Colon. Rectum. 2001, 44, 1319-23.
197. Elder, D.J., Baker, J.A., Banu, N.A., Moorghen, M., Paraskeva, C. Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J. Pathol. 2002, 198, 428-34.
198. Azumaya, M., Kobayashi, M., Ajioka, Y., et al. Size-dependent expression of cyclooxygenase-2 in sporadic colorectal adenomas relative to adenomas in patients with familial adenomatous polyposis. Pathol. Int. 2002, 52, 272-6.
199. Dobbie, Z., Muller, P.Y., Heinimann, K., et al. Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam. Anticancer Res. 2002, 22, 2215-20.
200. Sano, H., Kawahito, Y., Wilder, R.L., et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995, 55, 3785-9.
201. Gustafson-Svard, C., Lilja, I., Hallbook, O., Sjodahl, R. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 1996, 38, 79-84.
202. Berg, J., Christoph, T., Bodenteich, A., Towart, R. Heterogeneous distribution of COX-2 over-expression in human colon carcinoma cells. Adv. Exp. Med. Biol. 1997, 433, 327-30.
203. Dimberg, J., Samuelsson, A., Hugander, A., Soderkvist, P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999, 45, 730-2.
204. Shao, J., Sheng, H., Aramandla, R., et al. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 1999, 20, 185-91.
205. Sheehan, K.M., Sheahan, K., O'Donoghue, D.P., et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999, 282, 1254-7.
206. Masunaga, R., Kohno, H., Dhar, D.K., et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin. Cancer Res. 2000, 6, 4064-8.
207. Soslow, R.A., Dannenberg, A.J., Rush, D., et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000, 89, 2637-45.
208. Kojima, M., Morisaki, T., Uchiyama, A., et al. Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann. Surg. Oncol. 2001, 8, 458-65.
209. Zhang, H., Sun, X.F. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am. J. Gastroenterol. 2002, 97, 1037-41.
210. Tstjii, M., Kawano, S., DuBois, R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA 1997, 94, 3336-40.
211. Tomozawa, S., Nagawa, H., Tsuno, N., et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br. J. Cancer 1999, 81, 1274-9.
212. Steinbach, G., Lynch, P.M., Phillips, R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342, 1946-52.
213. Phillips, R.K., Wallace, M.H., Lynch, P.M., et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002, 50, 857-60.
214. Hallak, A., Alon-Baron, L., Shamir, R., et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig. Dis. Sci. 2003, 48, 1998-2002.
215. Rahme, E., Barkun, A.N., Toubouti, Y., Bardou, M. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 2003, 125, 404-12.
216. Arguedas, M.R., Heudebert, G.R., Wilcox, C.M. Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients, a decision analysis. Aliment. Pharmacol. Ther. 2001, 15, 631-8.